Fundraising Fox
Vanqua Bio
Chicago, US · Founded 2019 · 36 employees on LinkedIn · 11 known investors
Find your way into Vanqua Bio
Sign up to see every warm intro you have to Vanqua Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vanqua Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions. It serves patients with these diseases through its drug discovery and development work.
Founders & leadership
Board
Investors · 11
How we know: Avoro Capital Advisors's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: OrbiMed's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · avorocapital.com · the VCSheet dataset · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: avorocapital.com · Not right? Tell us
How we know: a partner's Signal profile · avorocapital.com · Not right? Tell us
Also in the syndicate · 5
Reported raises · per SEC filings
Form D private placements$136M disclosed across 3 rounds · 2019–2024
▶$45MraisedJul 2024 · 12 investors · BiotechnologyRule 506(b)
- Jonathan SilversteinDirector
- Rand SutherlandDirector
- Bernard DavitianDirector
- Uya ChuluunbaatarDirector
- James SullivanExecutive Officer, Director
- Mona AshiyaDirector
- Offering amount
- $45M
- Amount sold
- $45M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedSep 2021 · 11 investors · BiotechnologyRule 506(b)
- Mona AshiyaDirector
- Viola MeehanExecutive Officer
- Bernard DavitianDirector
- Sara NayeemDirector
- James SullivanExecutive Officer, Director
- Jonathan SilversteinDirector
- Stephen SquintoDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6MraisedOct 2019 · 1 investors · Other TechnologyRule 506(b)
- JONATHAN SILVERSTEINExecutive Officer, Director
- JAMES SULLIVANExecutive Officer, Director
- MONA ASHIYADirector
- Offering amount
- $18M
- Amount sold
- $6M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vanqua Bio do?
- Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions. It serves patients with these diseases through its drug discovery and development work.
- Who are Vanqua Bio's investors?
- Vanqua Bio's investors include Avoro Capital Advisors, OrbiMed, OUP (Osage University Partners), Pontifax Venture Capital, Casdin Capital, Omega Funds.
- How much funding has Vanqua Bio raised?
- Vanqua Bio has disclosed $136M raised across 3 rounds.
- Where is Vanqua Bio headquartered?
- Vanqua Bio is headquartered in Chicago, US.